Overall market sentiment has been down on Mirum Pharmaceuticals Inc (MIRM) stock lately. MIRM receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.
Mirum Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on MIRM!
Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With MIRM Stock Today?
Mirum Pharmaceuticals Inc (MIRM) stock is trading at $25.42 as of 11:54 AM on Thursday, Mar 28, an increase of $0.30, or 1.19% from the previous closing price of $25.12. The stock has traded between $25.14 and $25.79 so far today. Volume today is light. So far 61,444 shares have traded compared to average volume of 539,970 shares.
To see InvestorsObserver's Sentiment Score for Mirum Pharmaceuticals Inc click here.
More About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Click Here to get the full Stock Report for Mirum Pharmaceuticals Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
